Geron: RYTELO Ramp and Phase 3 Optionality Create a Tactical Long — Competition Is a Real Check
Geron is moving from development to commercial execution. RYTELO generated $184M in 2025 revenue and management guides $220-240M for 2026, while the company carries enough cash to fund near-term priorities. The Phase 3 program in JAK-inhibitor relapsed/refractory myelofibrosis is the key optionality that could re-rate valuation, but intensifying co…